| Megan Pokorney, | |
|
227 Shoreline Hwy, Mill Valley, CA 94941-3678 | |
| (415) 380-8402 | |
| Not Available |
| Full Name | Megan Pokorney |
|---|---|
| Gender | Female |
| Speciality | Pharmacist |
| Location | 227 Shoreline Hwy, Mill Valley, California |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1629527510 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | 75076 (California) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Megan Pokorney, 227 Shoreline Hwy, Mill Valley, CA 94941-3678 Ph: () - | Megan Pokorney, 227 Shoreline Hwy, Mill Valley, CA 94941-3678 Ph: (415) 380-8402 |
News Archive
High levels of the stress hormone cortisol strongly predict cardiovascular death among both persons with and without pre-existing cardiovascular disease according to a new study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM).
A single bone mineral density (BMD) test given 15 years earlier predicted a woman's risk of developing fractures to her spine over time, according to the largest and longest prospective study of osteoporosis.
Resverlogix Corp. announced today that it has officially activated the first site for the ASSURE 1 trial and commenced enrollment of patients for dosing of RVX-208. ASSURE 1 is the second Resverlogix Phase 2 clinical trial, led by Cleveland Clinic. This trial will examine RVX-208, Resverlogix's oral small molecule therapy for the treatment of atherosclerosis, in patients with acute coronary syndrome (ACS). This preparatory acute coronary syndrome study will ensure that 50 percent of the enrolled patients receive the IVUS (intravascular ultrasound) assessment.
Soligenix, Inc., a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that it has initiated a Phase 2, randomized, double-blind, placebo-controlled study evaluating orBec (oral beclomethasone 17,21-dipropionate or BDP) as a treatment for the gastrointestinal manifestations of chronic Graft-versus-Host disease.
University of Alabama at Birmingham researchers report the first documentation that suppressing a key cell-signaling pathway in a rat model of Parkinson's disease reduces pathogenesis. Oral administration of AZD1480 — one of the JAK/STAT pathway inhibitors generally known as Jakinibs — lessened the destructive inflammation and nerve cell degradation in the area of the brain affected by Parkinson's.
› Verified 5 days ago
Ms. Judy Lynn Burgio, R.PH., C.N. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 305 Morning Sun Ave, Mill Valley, CA 94941 Phone: 415-383-1908 Fax: 415-389-8566 | |
Tiffany Wai Ying Luk, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 227 Shoreline Hwy, Mill Valley, CA 94941 Phone: 415-380-8402 | |
Dina Shouman, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 227 Shoreline Hwy, Mill Valley, CA 94941 Phone: 415-380-8402 | |
Ms. Sheree Lyn Reed, PHARM.D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 800 Redwood Hwy, Frontage Rd #10, Mill Valley, CA 94941 Phone: 415-360-9020 Fax: 415-360-9021 | |
Dr. Lauren Marie Cunico, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 759 E Blithedale Ave, Mill Valley, CA 94941 Phone: 415-389-8891 | |
Dr. Veronica Hiu Wai Ma, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1 Camino Alto, Mill Valley, CA 94941 Phone: 415-388-2701 | |
Chunbaixue Yang, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 759 E Blithedale Ave, Mill Valley, CA 94941 Phone: 415-389-8891 |